Fuad El-Hibri and Healthcare Reform
Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University. The 6th annual healthcare conference was held on April 9, 2010 in New Haven, CT. The conference topic was “Re-Forming Healthcare: Excellence in a Transforming [...]
In: Emergent BioSolutions, Fuad El-Hibri, Health Care, Yale University · Tagged with: Emergent BioSolutions, Fuad El-Hibri, Health Care, United States, Yale University
500 Most Influential Muslims: Science and Technology
The Prince Alwaleed Bin Talaal Center for Muslim-Christian Understanding and The Royal Islamic Strategic Studies Centre published its first edition in what promises to be an annual series of insight into the movers and shakers of the Muslim world. Entitled The 500 Most Influential Muslims 2009, the book categorizes Muslims’ influential capacities into 15 [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri · Tagged with: Emergent BioSolutions, Muslim world, United States, Washington DC.
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
In: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Management, Strategic National Stockpile, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States
Bad News Clouds Two Bio Defense Stocks
Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Management, Shareholders, U.S. Department Of Health And Human Services · Tagged with: BARDA, Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, Federal government of the United States, Fuad El-Hibri, Strategic National Stockpile, United States, United States Department of Health and Human Services
Emergent BioSolutions Enhances Manufacturing Infrastructure with Strategic Acquisition in Baltimore
Emergent acquires manufacturing facility from MdBio and land from City of Baltimore for $8.2 million
ROCKVILLE, MD, November 13, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore [...]
In: Fuad El-Hibri · Tagged with: Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Martin O'Malley, Maryland, State of Maryland, United States
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri · Tagged with: Anthrax vaccines, Board of directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, U.S. Food and Drug Administration, United States
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
ROCKVILLE, MD, November 19, 2007 —Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax® (Anthrax Vaccine Adsorbed) under the current contract for 18.75 million doses that provides for a firm fixed price of $400 million plus an additional $34 [...]
In: Biothrax, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Clinical trial, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Food and Drug Administration, United States
Fuad El-Hibri From Wikipedia
Fuad El-Hibri (born March 2, 1958) is an American businessman, and CEO of Emergent BioSolutions http://en.wikipedia.org/wiki/Fuad_El-Hibri
Fuad El-Hibri (born March 2, 1958) in Hildesheim, Germany, spent his childhood equally in Europe and the Middle East before coming to the USA to get an economics degree from Stanford and an MBA from Yale.
Mr.El-Hibri earned a Masters Degree [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services · Tagged with: Board of directors, Booz Allen Hamilton, Mergers and acquisitions, Middle East, Saudi Arabia, Stanford University, United States, Yale University
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES REMAINS COMMITTED TO PROCUREMENT OF BIOTHRAX® UNDER CURRENT CONTRACT
ROCKVILLE, MD, November 19, 2007 —Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Department of Health and Human Services (HHS) has reaffirmed its commitment to continue to purchase BioThrax® (Anthrax Vaccine Adsorbed) under the current contract for 18.75 million doses that provides for a firm fixed price of $400 million plus an additional $34 [...]
In: Biothrax, Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Business, Chief executive officer, Clinical trial, Emergent BioSolutions, Infectious disease, Private Securities Litigation Reform Act, U.S. Food and Drug Administration, United States
Joe M. Allbaugh, Former Fema Director, Joins Emergent Biosolutions’ Board Of Directors
Emergency Preparedness Expert to Assist Emergent’s Commitment to Protecting Military and First Responders Against Biological Threats
GAITHERSBURG, MD., July 12, 2006 — Emergent BioSolutions today announced that Joe M. Allbaugh, who served as the Director of the Federal Emergency Management Agency (FEMA) under President George W. Bush from 2001 to 2003, has joined its Board of [...]
In: Board of directors, Emergent BioSolutions, Fuad El-Hibri · Tagged with: Chief executive officer, Emergency management, Federal Emergency Management Agency, George W Bush, Joe Allbaugh, Oklahoma City, September 11 attacks, United States